Michael Huang
Director/Board Member at Viracta Subsidiary, Inc.
Network origin in Michael Huang first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 18 | |
Windgap Medical, Inc.
 Windgap Medical, Inc. Pharmaceuticals: MajorHealth Technology Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.
10
| Subsidiary | Biotechnology | 10 |
Regenacy Pharmaceuticals LLC
 Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Digestive Health Specialists PC
3
| Private Company | 3 | |
Elixiron Immunotherapeutics, Inc.
 Elixiron Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elixiron Immunotherapeutics, Inc. is a privately-held biotechnology company based in Taipei, Taiwan. The Taiwanese company is focused on developing next-generation immunotherapies for unmet needs in immunological and degenerative diseases, as well as cancer. The company's drug discovery engine has allowed them to advance two clinical stage assets and several early-stage candidates. The CEO of the company is Hung-Kai Chen.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Michael Huang via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ARQULE, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Thomas Jefferson University | College/University | Corporate Officer/Principal | |
| Janssen R&D Ireland Ltd. | President | ||
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Undergraduate Degree | |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Roche Diagnostics Corp.
 Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN. | Medical Specialties | Corporate Officer/Principal | |
| San Diego State University | College/University | Undergraduate Degree Masters Business Admin | |
| Columbia College (California) | College/University | Undergraduate Degree | |
| The Johns Hopkins University | College/University | Doctorate Degree Undergraduate Degree Graduate Degree | |
| Sidney Kimmel Medical College | College/University | Corporate Officer/Principal | |
| King's College London | College/University | Doctorate Degree | |
Institute of Human Virology
 Institute of Human Virology Other Consumer ServicesConsumer Services The Institute of Human Virology (IHV) is a research institute located in Baltimore, MD, affiliated with the University of Maryland School of Medicine. The IHV is the first research institute in the US to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments for chronic viral diseases such as HIV/AIDS, hepatitis C, hepatitis B, and human papillomavirus infection. The IHV serves approximately 5,000 patients through six Baltimore area clinics and more than 500,000 patients in seven African and two Caribbean nations. The IHV also provides compassionate cutting-edge care and specializes in the treatment of HIV/AIDS and other chronic viral diseases. | Other Consumer Services | Chairman | |
| State University of New York at Downstate Medical Center | College/University | Doctorate Degree | |
| PREDICTIVE ONCOLOGY INC. | Medical Specialties | Chief Tech/Sci/R&D Officer Director/Board Member Chief Executive Officer | |
| CONTRAFECT CORPORATION | Biotechnology | Chief Executive Officer Director/Board Member | |
| Johnson & Johnson Pharmaceutical Group | Corporate Officer/Principal | ||
| Harvard Medical School | College/University | Doctorate Degree | |
Acetylon Pharmaceuticals, Inc.
 Acetylon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| SERES THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
Agency For Science Technology & Research Ventures
 Agency For Science Technology & Research Ventures Investment ManagersFinance Agency For Science Technology & Research Ventures is a Venture Capital firm, a subsidiary of Agency for Science, Technology & Research founded in 1991 with headquartered in Singapore. | Investment Managers | Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| The Johns Hopkins University School of Medicine | College/University | Doctorate Degree | |
| CUE BIOPHARMA, INC. | Biotechnology | Chairman | |
| GLG PHARMA S.A. | Pharmaceuticals: Major | Chief Operating Officer Director/Board Member | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| C4 THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO Director/Board Member | |
X-Vax Technology, Inc.
 X-Vax Technology, Inc. BiotechnologyHealth Technology X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
| Janssen Therapeutics, Inc. | President | ||
| Brink Biologics, Inc. | Chief Executive Officer | ||
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Pharmaceuticals: Major | Director/Board Member | |
| IMMUNITYBIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
AI Proteins, Inc.
 AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NextRNA Therapeutics, Inc.
 NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Biotechnology | Director/Board Member Director/Board Member | |
| ALOPEXX, INC. | Biotechnology | Director/Board Member |
Statistics
International
| United States | 45 |
| Ireland | 2 |
| United Kingdom | 2 |
| Israel | 2 |
| Singapore | 2 |
Sectoral
| Health Technology | 28 |
| Consumer Services | 14 |
| Finance | 3 |
| Distribution Services | 2 |
| Commercial Services | 2 |
Operational
| Director/Board Member | 174 |
| Corporate Officer/Principal | 80 |
| Director of Finance/CFO | 57 |
| Chief Executive Officer | 45 |
| Independent Dir/Board Member | 44 |
Most connected contacts
| Insiders | |
|---|---|
| Daniel Geffken | 53 |
| Jim Woody | 31 |
| Ivor Royston | 30 |
| Roger Pomerantz | 30 |
| William Chin | 21 |
| William McKee | 20 |
| J. Engle | 19 |
| Gur Roshwalb | 17 |
| Nicole Onetto | 17 |
| Barry Simon | 15 |
| Jane Barlow | 15 |
| Richard L. Gabriel | 14 |
| Timothy Adam Krochuk | 13 |
| Thomas Darcy | 13 |
| Richard Ghalie | 13 |
- Stock Market
- Insiders
- Michael Huang
- Company connections
